Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma

The development of BRAF and MEK inhibitors (BRAFi/MEKi) has led to major advances in melanoma treatment. However, the emergence of resistance mechanisms limits the benefit duration and a complete response occurs in less than 20% of patients receiving BRAFi ± MEKi. In this study, we evaluated the imp...

Descripción completa

Detalles Bibliográficos
Autores principales: Reger de Moura, Coralie, Vercellino, Laetitia, Jouenne, Fanélie, Baroudjian, Barouyr, Sadoux, Aurélie, Louveau, Baptiste, Delyon, Julie, Serror, Kevin, Goldwirt, Lauriane, Merlet, Pascal, Bouquet, Fanny, Battistella, Maxime, Lebbé, Céleste, Mourah, Samia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2019
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6931208/
https://www.ncbi.nlm.nih.gov/pubmed/31874374
http://dx.doi.org/10.1016/j.tranon.2019.10.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6931208/
https://www.ncbi.nlm.nih.gov/pubmed/31874374
http://dx.doi.org/10.1016/j.tranon.2019.10.003

Ejemplares similares